Nuveen’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.54M Sell
232,596
-469
-0.2% -$13K ﹤0.01% 1835
2025
Q4
$6.46M Sell
233,065
-4,275
-2% -$109K ﹤0.01% 1793
2025
Q3
$5.76M Buy
237,340
+5,440
+2% +$108K ﹤0.01% 1839
2025
Q2
$3.94M Buy
231,900
+32,020
+16% +$558K ﹤0.01% 1994
2025
Q1
$3.9M Buy
199,880
+18,244
+10% +$478K ﹤0.01% 2042
2024
Q4
$4.5M Sell
181,636
-2,960
-2% -$75.5K ﹤0.01% 2029
2024
Q3
$4.52M Hold
184,596
﹤0.01% 2036
2024
Q2
$4.33M Buy
184,596
+10,405
+6% +$256K ﹤0.01% 2027
2024
Q1
$5.76M Sell
174,191
-3,444
-2% -$107K ﹤0.01% 1913
2023
Q4
$4.84M Sell
177,635
-3,055
-2% -$75.9K ﹤0.01% 1998
2023
Q3
$4.35M Buy
180,690
+9,606
+6% +$258K ﹤0.01% 1936
2023
Q2
$5.46M Sell
171,084
-30,057
-15% -$975K ﹤0.01% 1869
2023
Q1
$6.16M Sell
201,141
-29,167
-13% -$1.15M ﹤0.01% 1772
2022
Q4
$9.01M Sell
230,308
-12,649
-5% -$567K ﹤0.01% 1561
2022
Q3
$11.6M Buy
242,957
+13,491
+6% +$770K ﹤0.01% 1392
2022
Q2
$8.88M Buy
229,466
+17,413
+8% +$692K ﹤0.01% 1582
2022
Q1
$12.5M Buy
212,053
+8,937
+4% +$586K ﹤0.01% 1500
2021
Q4
$16.2M Buy
203,116
+7,619
+4% +$652K ﹤0.01% 1362
2021
Q3
$20.1M Buy
195,497
+9,938
+5% +$998K 0.01% 1269
2021
Q2
$23.9M Buy
185,559
+16,429
+10% +$1.31M 0.01% 1224
2021
Q1
$13.5M Sell
169,130
-33,166
-16% -$3.16M ﹤0.01% 1607
2020
Q4
$16.5M Buy
202,296
+71,925
+55% +$3.54M 0.01% 1372
2020
Q3
$3.21M Buy
130,371
+68,697
+111% +$1.7M ﹤0.01% 2140
2020
Q2
$1.73M Buy
61,674
+15,581
+34% +$336K ﹤0.01% 2404
2020
Q1
$830K Buy
+46,093
New +$1M ﹤0.01% 2593

Other funds holding BEAM

Nuveen's BEAM Position: Q1 2026 in Review

Nuveen reduced its Beam Therapeutics (BEAM) stake by 0.2% in Q1 2026, selling an estimated $13K and leaving 232,596 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1835.

Nuveen first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $23.9M in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Nuveen held 232,596 shares of Beam Therapeutics worth $5.54M as of Q1 2026.
  • Nuveen sold 469 Beam Therapeutics shares in Q1 2026, an estimated $13K.
  • Beam Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1835 holding.
  • Nuveen first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Nuveen's Beam Therapeutics position peaked at $23.9M in Q2 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.